We Offer Worldwide Shipping
Login Wishlist

5′-Adenylic acid

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-A3036

  • Specification : 98%

  • CAS number : 61-19-8

  • Formula : C10H14N5O7P

  • Molecular Weight : 347.22

  • Volume : 100mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-A3036

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

347.22

Appearance

powder

Botanical Source

Structure Type

Nucleosiede

Category

SMILES

Synonyms

IUPAC Name

Density

2.3±0.1 g/cm3

Solubility

Flash Point

436.7±35.7 °C

Boiling Point

798.5±70.0 °C at 760 mmHg

Melting Point

178-185 °C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2934990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:61-19-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

32611911

Abstract

The novel coronavirus disease 2019 (COVID-19) with its early origin from Wuhan city in China has evolved into a global pandemic. Maximal precautionary measures and resources have been put forward by most nations in war footing to mitigate transmission and decrease fatality rates. This article was aimed to review the evidence on clinical management and to deal with the identification of high-risk groups, warning signs, appropriate investigations, proper sample collection for confirmation, general and specific treatment measures, strategies as well as infection control in the healthcare settings. Advanced age, cardiovascular disease, diabetes, hypertension and cancer have been found to be the risk factors for severe disease. Fever lasting for >five days with tachypnoea, tachycardia or hypotension are indications for urgent attention and hospitalization in a patient with suspected COVID-19. At present, reverse transcription-polymerase chain reaction (RT-PCR) from the upper respiratory tract samples is the diagnostic test of choice. While many drugs have shown in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there are insufficient clinical data to promote or dissuade their usage. Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.

KEYWORDS

Clinical management - corticosteroids - COVID-19 - hydroxychloroquine - lopinavir - remdesivir - risk groups - SARS-CoV-2.

Title

George M Varghese 1, Rebecca John 1, Abi Manesh 1, Rajiv Karthik 1, O C Abraham 2

Author

George M Varghese 1, Rebecca John 1, Abi Manesh 1, Rajiv Karthik 1, O C Abraham 2

Publish date

2020 May

PMID

32597995

Abstract

Coronavirus disease 2019 (COVID-19) is an unprecedented pandemic that has particularly affected nursing homes and long-term care facilities. To support frontline health care professionals caring for older adults, the current article provides guidance on strategies to optimize medication management within nursing homes and long-term care facilities. In addition, the article reviews two medications that have been granted U.S. Food and Drug Administration emergency use authorization for treatment of COVID-19: hydroxychloroquine and remdesivir. Finally, this article highlights resources and strategies for improving communication among an interprofessional team during the ongoing pandemic, as well as education on COVID-19. Although the COVID-19 pandemic has had many negative implications, it has also brought to attention opportunities to improve the delivery of care and increase the importance of working as an interprofessional team (“village”) during these challenging times. [Journal of Gerontological Nursing, 46(7), 3-8.].

Title

Optimizing Medication Management During the COVID-19 Pandemic: It Takes a Village

Publish date

2020 Jul 1;

PMID

32573538

Abstract

The article provides a review of foreign literature for 2020 on existing methods of drug treatment of coronavirus disease COVID-19. To date, in the treatment of COVID-19 in different countries, a little more than 10 drugs are used. The largest number of studies on the testing of these drugs is carried out by scientists from China, the USA, and European countries. It should be noted that among these drugs there is not a single new drug developed specifically for the treatment of COVID-19, the recommended and used drugs have previously been used to treat, as a rule, diseases of the viral etiology, less often another pathology. These suggestions are often based on analogy, the hypothesis of their supposed effectiveness for COVID-19. It can be assumed that a brake on the development of a drug specific for coronavirus disease is a poor knowledge of the pathogenesis of virus invasion in the body’s adhesives and the development of complications. The review provides detailed literature data on drugs such as hydroxychloroquine / chloroquine, lopinavir/natinavir, remdesivir, ACE inhibitors and angiotensin converting enzyme receptor blockers, tissue plasminogen activator, as well as plasma transfusion transfusions.

KEYWORDS

coronavirus disease COVID-19; drugs; proven efficacy of drugs; treatment methods.

Title

[Drug treatment of coronavirus disease COVID-19: evidence exists?]

Author

Sh V Timerbulatov 1, M V Timerbulstov 1, E N Gainullina 1, A R Gafarova 1, V M Timerbulatov 1

Publish date

2020


Description :

Empty ...